Abstract
BackgroudTo evaluate the relationship between omentin-1 and benign prostatic hyperplasia (BPH). BPH is the most common urological disease in elderly men worldwide. Lower serum omentin-1 levels were reported to be negatively associated with the incidence of inflammation, diabetes, obesity and metabolic syndrome, which all play a role in the development of BPH. To the best of our knowledge, the relationship between omentin-1 and BPH has not been investigated previously.MethodsA total of 70 males participated in this study, including forty patients diagnosed with BPH and thirty healthy males. The anthropometric measurements and the biochemical parameters were measured in this study. We evaluated serum omentin-1 levels and the correlation with those data. We also test the gene expression of IL-8, IL-18 in BPH group using the TURP tissues.ResultsThe serum omentin-1 levels were lower in the BPH patients than in the control group (27.95 ± 4.18 versus 32.03 ± 5.46, p < 0.001). The general characteristics and biochemical parameters were investigated, and a negative correlation was found between serum omentin-1 levels and BMI in the BPH group (r = − 0.391, p = 0.013) as well as the whole group (r = − 0.457, p < 0.001). Multiple-factor binary regression analysis revealed that serum omentin-1was a protective factor of BPH development. Furthermore, lower serum omentin-1 levels were associated with higher mRNA expression of IL-8 or IL-18 in the BPH group.ConclusionOmentin-1 may suppress the development of BPH and Lower serum omentin-1 levels in BPH patients might associated with higher prostate volume and higher IL-8 and IL-18 expression levels in their prostatic cells.
Highlights
Backgroud: To evaluate the relationship between omentin-1 and benign prostatic hyperplasia (BPH)
The general characteristics and biochemical parameters were investigated, and a negative correlation was found between serum omentin-1 levels and Body mass index (BMI) in the BPH group (r = − 0.391, p = 0.013) as well as the whole group (r = − 0.457, p < 0.001)
Multiple-factor binary regression analysis revealed that serum omentin1was a protective factor of BPH development
Summary
A total of 70 males participated in this study, including forty patients diagnosed with BPH and thirty healthy males. Forty patients diagnosed with BPH who needed transurethral resection of the prostate (TURP) and thirty healthy males matched by age were assigned into two groups: the BPH group and the control group (CG). The prostate size of CG measured by ultrasound is less than 4 cm × 3 cm × 2 cm and IPSS is less than 7. The anthropometric measurements obtained in this study included height, weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), and waist circumference (WC). Fasting blood samples were obtained to analyze blood urea nitrogen (BUN), triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL), creatinine, prostate-specific antigen (PSA) and glucose levels using standard methods. Prostate size was measured by ultrasound and the prostate volume (PV) was calculated from transverse images by using the prolate-ellipsoid formula: 0.524 × height×width×length [9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
